Results 181 to 190 of about 4,644,977 (251)

Adjuvant mecobalamin for anti-VEGF therapy in retinal vein occlusion: protocol of a single-centre, randomised, double-blinded controlled trial. [PDF]

BMJ Open
Liu KY, Luo QY, Li ZY, Xiao RY, Zeng C, Zhang XD, Liu SL, Deng WL, Zhang YL.   +8 more
europepmc   +1 more source

Long term evolutions of hard exudates after anti-VEGF therapy for diabetic macular oedema. [PDF]

Eye (Lond)
Pak K, Yoon C, Sadda SR.
europepmc   +1 more source

Complement Activation Linked to Type II Interferon Signaling in Still Disease

Arthritis &Rheumatology, EarlyView.
Objective Still disease (SD) is an autoinflammatory syndrome characterized by innate immune dysregulation. Although complement can drive inflammation, its involvement in SD remains to be defined. Thus, we aimed to assess complement activation in SD. Methods Complement was assessed using transcriptomic, proteomic, and in vitro approaches. RNA sequencing
Freya M. C. H. Huijsmans, Tabea Thalheim, Alejandra Bodelón, Greta Rogani, Lyanne J. P. M. Sijbers, Remco G. A. Erkens, Aafke de Ligt, Rianne Scholman, Aron Brinker, Gisella B. Beretta, Nienke M. Ter Haar, Thomas Vogl, Johannes Roth, Trang T. Duong, Sytze de Roock, Joost F. Swart, Deborah A. Marshall, Susanne M. Benseler, Rae S. M. Yeung, Christoph Kessel, Sebastiaan J. Vastert, Emely L. Verweyen, Jorg van Loosdregt, on behalf of the UCAN CAN‐DU/UCAN CURE Consortia and the One Child Every Child Initiative, Adam Huber, Bianca Lang, Chelsea DeCoste, Elizabeth Stringer, Suzanne Ramsey, Alan Rosenberg, Kate Neufeld, Mehul Jariwala, Tristan Kerr, Alexander Mosoiu, Alisa Rachlis, Amy Xu, Arthur Cheng, Brenleigh Jebb, Brian Feldman, Bruno Pereira, Deborah Levy, Dilan Dissanayake, Elizaveta Limenis, Evelyn Rozenblyum, Harper Cheng, Jennifer Ji Young Lee, Lynn Spiegel, Rayfel Schneider, Ronald Laxer, Ruud Verstegen, Shirley Tse, Andrea Human, David Cabral, Herman Tam, Jaime Guzman, Kim Morishita, Kristin Houghton, Lori Tucker, Mercedes Chan, Ross Petty, Tommy Gerschman, Annet van Royen‐Kerkhof, Berent Prakken, Erika Van Nieuwenhove, Marc Jansen, Nico Wulffraat, Ciarán Duffy, Nadia Luca, Roman Jurencak, Tala El Tal, Claire LeBlanc, Gaëlle Chédeville, Piya Lahiry, Rosie Scuccimarri, Sarah Campillo, Clare Hutchinson, Daniah Basodan, Dax G Rumsey, Hon Yan Ng, Jeanine McColl, Lillian Lim, Tara McGrath, Danielle Brinkman, Petra Hissink Muller, Elizabeth Legger, Wineke Armbrust, Ellen Schatorje, Esther Hoppenreijs, Elodie Boudes, Gillian Currie, Heinrike Schmeling, Muhammed Dhalla, Nicole Johnson, Paivi Miettunen, Ravneet Sran, Rebeka Stevenson, Erkan Demirkaya, Jonathan Park, Roberta Berard, Giske Biesbroek, Mariken Gruppen, Gordon Soon, Joseph Cafazzo, Liane Heale, Michelle Batthish, Tania Cellucci, Lily Lim, Maarten IJzerman, Marinka Twilt, Marleen Verkaaik, Philomine van Pelt, Sylvia Kamphuis, Michelle Kip, Nicholas Blanchette, Paul Dancey, Regina de Geus   +115 more
wiley   +1 more source

Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval. [PDF]

Clin Ophthalmol
Şatırtav G, Lövestam-Adrian MK, Chang W, Charles M, Chen LJ, Cheung CMG, Kodjikian L, Ohji M, Zinkernagel M, Wolf S.   +9 more
europepmc   +1 more source

Sema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity‐driven fibrosis

Arthritis &Rheumatology, Accepted Article.
Objective We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro. Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=
Jaime Marty, Sara Martinez‐Ramos, Carlos Rafael‐Vidal, Beatriz Malvar‐Fernández, Tiago Carvalheiro, Ralph G. Tieland, Ines Ramos, Wiola Marut, Ana Pinheiro‐Lopes, Ana Argibay, Brenda Maure, Caritina Vázquez‐Triñanes, Nair Pérez Gómez, David Fernández‐Fernández, Sandra Vila, Coral Mouriño, Rogier M Thurlings, Arjan van Caam, Alberto Rivera, José María Pego‐Reigosa, Timothy R. Radstake, Samuel Garcia   +21 more
wiley   +1 more source

"Brake" and "accelerator": revisiting tumor cell direct responses and the paradox of aggression in anti-VEGF therapy. [PDF]

Front Immunol
Wei P, Li J, Cheng X, Lu Y, Xia Q, Wang Z.   +5 more
europepmc   +1 more source

Spatial Proteomics Identifies Distinct Synovial Microenvironments in Hip and Knee Osteoarthritis

Arthritis &Rheumatology, Accepted Article.
Objective Osteoarthritis (OA) is a heterogeneous joint disease, yet mechanistic insights derive predominantly from knee OA and are often extrapolated to other joints. We investigated joint‐associated differences in the spatial molecular organization of hip and knee OA synovium.
Peng Xie, Antonia R. Sun, Zhengtan Zheng, Yunkun Qu, Feng Gao, Christina Theodoropoulos, Nicholas Matigian, Zhiyong Li, Ross Crawford, Indira Prasadam   +9 more
wiley   +1 more source

Baseline microperimetry and metabolic status predict functional outcomes in diabetic macular oedema: a prospective cohort study of anti-VEGF therapy. [PDF]

Ann Med
Deng WL, Liu KY, Li ZY, Zhang XD, Zhang YL, Liu SL.   +5 more
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Timing of anti-VEGF therapy and postoperative macular edema after cataract surgery in eyes with retinal vein occlusion: a retrospective cohort study. [PDF]

BMC Ophthalmol
Dahlan K, Oganov A, Fazio N, Chaudhary KM.   +3 more
europepmc   +1 more source